Trial Profile
A randomized double-blind placebo-controlled study to assess the safety in a one-year of orally administered microencapsulated ragweed pollen extract.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Ragweed allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors Curalogic
- 22 Jul 2011 New trial record